Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Alan B, Colowick"'
Publikováno v:
Blood. 96:1698-1702
The development of inhibitory antibodies to factor VIII (FVIII) occurs in approximately 30% to 40% of patients with severe hemophilia A. Management options for patients with inhibitor include eradicating it via immune tolerance induction (ITI) or tre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3aedaf22c040f77e0b076b75e19cfbd2
https://doi.org/10.1182/blood.v96.5.1698.h8001698_1698_1702
https://doi.org/10.1182/blood.v96.5.1698.h8001698_1698_1702
Autor:
Barry, Mirtsching, Veena, Charu, Saroj, Vadhan-Raj, Alan B, Colowick, Gregory, Rossi, Dianne, Tomita, William P, McGuire
Publikováno v:
Oncology (Williston Park, N.Y.). 16(10 Suppl 11)
The safety and efficacy of darbepoetin alfa (Aranesp) at 3.0 microg/kg administered every 2 weeks and recombinant human erythropoietin (rHuEPO) given as 40,000 U weekly or 150 U/kg three times weekly were evaluated by pooling data from three darbepoe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::813fecccbf16ed75212942b7cdff08e1
https://pubmed.ncbi.nlm.nih.gov/12435171
https://pubmed.ncbi.nlm.nih.gov/12435171
Autor:
Robert Pirker, Johan Vansteenkiste, Jaromir Musil, Bartomeu Massuti, Salvatore Siena, Dianne Tomita, Jenni Gateley, Albert Font, Fernando Barata, Michael Fiegl, Alan B. Colowick
Publikováno v:
Scopus-Elsevier
Background: Patients receiving chemotherapy often develop anemia. Darbepoetin alfa (Aranesp™) is an erythropoiesisstimulating glycoprotein that has been shown, in dosefinding studies, to be safe and clinically active when administered to patients w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::82eb17c5482bfcaf4596a1ee9c31a5c8
http://www.scopus.com/inward/record.url?eid=2-s2.0-0037151364&partnerID=MN8TOARS
http://www.scopus.com/inward/record.url?eid=2-s2.0-0037151364&partnerID=MN8TOARS
